390 results on '"Dun, Matthew D."'
Search Results
2. Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
3. EZHIP’s role in diffuse midline glioma: echoes of oncohistones?
4. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma
5. Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia
6. Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection
7. CAR T cell therapies for diffuse midline glioma
8. Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma
9. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology
10. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location
11. Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities
12. Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia
13. Global profiling of the proteomic changes associated with the post-testicular maturation of mouse spermatozoa
14. scTEM-seq: Single-cell analysis of transposable element methylation to link global epigenetic heterogeneity with transcriptional programs
15. Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection
16. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies
17. Acrylamide modulates the mouse epididymal proteome to drive alterations in the sperm small non-coding RNA profile and dysregulate embryo development
18. Proteomic Dissection of the Impact of Environmental Exposures on Mouse Seminal Vesicle Function
19. Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
20. Subchronic elevation in ambient temperature drives alterations to the sperm epigenome and accelerates early embryonic development in mice.
21. Molecular insights into the divergence and diversity of post-testicular maturation strategies
22. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models
23. Think zebras: challenges and opportunities for treating rare cancers
24. A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma
25. Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia
26. Capacitation and Acrosome Reaction: Histochemical Techniques to Determine Acrosome Reaction
27. Proteomic Profiling of Mouse Epididymosomes Reveals their Contributions to Post-testicular Sperm Maturation
28. Modification of Crocodile Spermatozoa Refutes the Tenet That Post-testicular Sperm Maturation Is Restricted To Mammals*
29. Pharmaco‐phosphoproteomic analysis of cancer‐associated KIT mutations D816V and V560G
30. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
31. Assessment of the impact of direct in vitro PFAS treatment on mouse spermatozoa
32. Phosphoproteomic analysis of the adaption of epididymal epithelial cells to corticosterone challenge.
33. Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement.
34. Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon
35. Proteomic Analysis of Human Spermatozoa
36. Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
37. Supplementary Figures 1-15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
38. Supplementary Data S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
39. Data from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
40. The abundance of a transfer RNA-derived RNA fragment small RNA subpopulation is enriched in cauda spermatozoa
41. Pharmaco-phosphoproteomic analysis of cancer-associated KITmutations D816V and V560G.
42. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
43. A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma
44. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
45. SYST-15 GENERATION AND MULTI-DIMENSIONAL PROFILING OF A CHILDHOOD CANCER CELL LINE ATLAS DEFINES NEW THERAPEUTIC OPPORTUNITIES
46. Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
47. Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
48. Mechanisms of tethering and cargo transfer during epididymosome-sperm interactions
49. Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies
50. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.